1-Pyrroline-5-carboxylic acid
|
Basic information |
| Metabolite name | 1-Pyrroline-5-carboxylic acid |
 | HMDB0001301 |
 |
C03912 |
 |
440162 |
| Synonyms | 1-pyrroline-5-carboxylate; |
| No. of studies | 5 |
|
Basic information |
| Metabolite name | 1-Pyrroline-5-carboxylic acid |
| HMDB0001301 |
|
C03912 |
|
440162 |
| Synonyms | 1-pyrroline-5-carboxylate; |
| No. of studies | 5 |
|
Relationship between 1-Pyrroline-5-carboxylic acid and depression (count: 5) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1020 | Type1 | CUMS group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M1020 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1020 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1135 | Type2 | PSD + electroacupuncture group vs. PSD group | Faece | Sprague-Dawley rat | Up |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M867 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |